The incorporation of a polymer into the spray drying process may have enhanced the bioavailability of the mangosteen rind powder. To clarify the relationship between mangosteen rind powder and schizophrenia or schizoaffective disorder the thesis describing the pilot study was revisited and interpreted. The health of the cell is compromised early in schizophrenia and affective disorder, evidenced by impaired antioxidant defences and oxidative stress. A neurobiological feature of schizophrenia is apoptosis (cell death). Higher levels of glutathione S-transferases are likely to promote cell viability instead of apoptosis and act as a biomarker for schizophrenia. Mangosteen rind powder is likely to improve the level of glutathione S-transferases; however an assay would potentially confirm this assumption. The pilot study confirms that mangosteen rind powder capsules show a positive signal of efficacy and effectiveness in schizophrenia and affective disorder for people without a co-morbid medical condition. The treatment was delivered safely and well tolerated amongst the cohort over a period of 180 days. These findings support the supplementation of mangosteen rind powder capsules at the dose of 1000mg/day for the augmented treatment of schizophrenia and affective disorders. The findings will also be discussed in terms of disability burden and the mental health system.